Search Results

TREP-SURE EIA is a qualitative enzyme immunoassay for the in vitro diagnostic detection of Treponema pallidum (syphilis) antibodies in human serum or plasma. This product can be used as an initial screening test or as a confirmatory diagnostic test, but is not cleared (approved) by the U.S. Food and Drug Administration (FDA) for use in screening blood or plasma donors.

Not Found

The provided regulatory document discusses the “Trep-Sure EIA Test” for the detection of Treponema pallidum (syphilis) antibodies. However, the document does not contain the detailed study information, acceptance criteria, or performance metrics typically found in a clinical study report or a more comprehensive FDA submission.

Specifically, the document lacks the following information required to answer the prompt thoroughly:

1. A table of acceptance criteria and the reported device performance.
2. Sample size used for the test set and the data provenance.
3. Number of experts used to establish the ground truth for the test set and their qualifications.
4. Adjudication method for the test set.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and the effect size.
6. If a standalone (algorithm only) performance study was done.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.) for the test set.
8. The sample size for the training set.
9. How the ground truth for the training set was established.

The document is a 510(k) clearance letter, which confirms that the device is substantially equivalent to a legally marketed predicate device. It briefly mentions the "Indications for Use" but does not provide the technical details of the performance study that led to this clearance.

Therefore, I cannot fulfill the request for information regarding acceptance criteria and study details based on the provided text.

Ask a specific question about this device